Advancing the Next Generation of Antibody Drugs

The World’s First Recombinant Polyclonal Drugs

GigaGen is advancing the first recombinant polyclonal antibody therapies for infectious disease and disorders of immune regulation. Recombinant polyclonals have the potential to transform the way diseases are treated and cured through:

• Simultaneous targeting of multiple pathogens, and multiple targets per pathogen
• Low toxicity due to natural immune system function
• High potency through selection of the best antibodies from the best immune responses

Polyclonal antibody therapies contain a diverse array of antibodies in a single product. They are an ideal modality for diseases that comprise many targets, such as viruses that are best neutralized by antibodies binding to multiple epitopes, and disorders of immune regulation.

Our drug discovery platform copies and recreates the best immune responses from human donors who are either vaccinated or convalescent for a particular disease. This approach ensures that the diversity of antibodies in our drug candidates closely mimics that of a natural immune response. 

Recombinant polyclonal antibodies are made in the laboratory versus being extracted from plasma. As such, they can be enriched or modified to create therapeutics that are more potent than what the natural immune response can provide. Produced from a single Master Cell Bank, GigaGen’s recombinant polyclonal antibodies are cost efficient and provide a streamlined regulatory process compared to a monoclonal cocktail.

• GIGA-2339: Hepatitis B Virus (HBV) Recombinant Polyclonal Antibody Therapeutic

GigaGen is developing a recombinant polyclonal therapeutic (GIGA-2339) to treat and potentially cure chronic HBV infection. GIGA-2339 is made in the laboratory and is over 2,000 times more potent than current plasma-derived anti-HBV hyperimmune drugs. It is composed of over 1,000 antibodies against HBV surface antigens, providing better viral antigen coverage that may potentially lead to improved clearance of the virus by the body’s natural immune cells.

• High Titer Recombinant Anti-Pathogen Polyclonal

GigaGen’s high titer polyclonal targets multiple specific pathogens, mirroring the antibody diversity found in healthy vaccinated or convalescent donors against specific common diseases. It has been engineered to have significantly higher potency than plasma-derived products that are currently used to treat patients with immunodeficiencies.

• Anti-Botulinum Neurotoxin Recombinant Polyclonal

GigaGen was awarded a contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA), valued at up to $135.2 million, to develop a high-potency recombinant polyclonal antibody drug designed to neutralize all seven botulinum neurotoxin (BoNT) variants and a second biothreat of interest to the agency. This work builds upon a previous contract awarded by the Department of Defense for BoNT. 

GigaGen’s collaboration with BARDA demonstrates how our platform can support rapid responses to biothreats and future pandemics. 

• Recombinant Human ATG Polyclonal

Anti-thymocyte globulin (ATG) is used with other medications to treat transplant rejection and other inflammatory diseases. GigaGen is developing a recombinant human ATG that is less immunogenic than animal plasma-derived ATG and more consistent from batch to batch. It has the potential to provide improved efficacy with a less frequent dosing regimen.

• Anti-Rabies Recombinant Polyclonal

GigaGen is developing a high-potency recombinant polyclonal anti-rabies product, which consists of thousands of antibodies against rabies.